2023-03-16 08:00
2023-03-13 16:00
The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2023-02-08 08:00
Biovica, active in cancer monitoring, today announces that the company’s test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market. “The CLIA certification...
2023-01-31 09:00
Biovica, active in cancer diagnostics, today announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers. The results, from an analysis of samples and clinical data from the SWOG S0226...
2022-12-15 08:00
Successful capital acquisition paves the way for launch in the USA Significant events during the second quarter Significant events after the end of the period Webcast: When: 15 December 2022 at 15.00 CET Where: registration via lyyti Broadcast language...
2022-12-13 22:00
Biovica, active in cancer monitoring, today announces that the company expects to receive CLIA certification in during first quarter 2023. The Laboratory Field Services (LFS) of California Department of Public Health (CDPH) has informed Biovica that it...
2022-12-07 08:00
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION...
2022-12-01 14:40
Biovica, active in cancer diagnostics, today announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market. Biovica’s...
2022-11-22 14:55
Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood test, will be presented as a poster at the world’s largest breast cancer symposium, SABCS, on December 8...
2022-11-22 14:50
Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world’s largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum®...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects